AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), GROK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

User:

Stage 1:
(Timestamp: 1 Year Prior to Admission)
A 50-year-old woman (residing in Delhi NCR, working remotely for an investment company, history of late-onset adult asthma diagnosed 1 year prior, allergic rhinitis, obesity, prediabetes, hyperlipidemia, depression) presents with 1 week of worsening dyspnea and acute exertional pleuritic chest pain radiating to her back.
HPI:
- 1 Year Ago: Diagnosed with late-onset asthma (PFT consistent with asthma, treated with fluticasone-salmeterol and albuterol with partial response). History of allergic rhinitis.
- 8 Months Ago: Mold identified in bathroom during home renovation.
- 1 Week Ago: Progressive dyspnea following second dose of COVID vaccine. Unresponsive to escalated inhaled steroids.
- Day of Admission: Acute pleuritic chest pain on exertion. No orthopnea, PND, fevers, chills, rashes, wheezing, or anosmia.
- Family History: Father with CAD (stent at 63). Mother/sister with titin cardiomyopathy, but patient tested negative for the mutation.

Resident:

Hello, Chief Resident here.

Key Findings:
A 50-year-old woman with late-onset adult asthma (poorly responsive to ICS), allergic rhinitis, mold exposure, and cardiovascular risk factors presenting with acute exertional pleuritic chest pain radiating to the back and worsening dyspnea.

Differential Diagnoses:
1. Pulmonary Embolism (40%): Sudden exertional pleuritic chest pain and dyspnea in an obese patient with recent systemic inflammatory trigger (vaccination).
2. Eosinophilic Granulomatosis with Polyangiitis (EGPA) (25%): Adult-onset asthma, allergic rhinitis, and poor response to inhaled steroids strongly suggest an underlying systemic vasculitis.
3. Acute Coronary Syndrome / Aortic Pathology (20%): Exertional chest pain radiating to the back in the setting of metabolic syndrome and strong CAD family history.
4. Hypersensitivity Pneumonitis (15%): Worsening exertional dyspnea following documented bathroom mold exposure.

Prioritized Diagnostic Tests:
1. CT Pulmonary Angiogram (CTPA): To rule out PE, aortic dissection, and assess lung parenchyma.
2. 12-lead ECG & Serial High-Sensitivity Troponins: To evaluate for ACS.
3. CBC with Differential: To check for peripheral hypereosinophilia.
4. ANCA Panel & Total Serum IgE: To evaluate for vasculitis/EGPA and allergic fungal etiology.
5. D-Dimer: For thrombotic risk stratification.

Attending:

Hello Attending Consultant here

Top 3 DDx:
1. EGPA (adult-onset asthma + rhinitis + steroid-refractory symptoms)
2. Acute PE (pleuritic pain + obesity + inflammatory trigger)
3. ABPA (mold exposure + poorly controlled asthma)

Critique/Improvements (6 points):
- CTPA first-line is appropriate but add non-contrast HRCT sequences for parenchymal/EGPA or HP evaluation.
- Immediate ECG + hs-Tn is mandatory; omit isolated D-dimer (low specificity post-vaccine).
- Add BNP + TTE to exclude occult cardiomyopathy (family hx) or myocarditis.
- Quantify eosinophils + IgE/ANCA urgently; peripheral eos >10% pivots to EGPA/ABPA.
- Include Aspergillus-specific IgE/precipitins given mold history.
- Defer ANCA until eos confirmed; avoid shotgun serologies.
- Risk-stratify ACS with HEART score given radiation to back.

Expert:

Hello, Expert Clinician here.

Best Unifying Diagnosis: EGPA — late-onset asthma, allergic rhinitis, and steroid-refractory dyspnea form the classic prodrome. Pleuritic pain may reflect eosinophilic pleuritis, pulmonary infiltrates, or—critically—eosinophilic myocarditis, EGPA's leading cause of death. EGPA also raises VTE risk, so PE remains a dangerous mimic, not an alternative.

Top Differentials:
- Acute PE: Fits pleuritic pain, obesity, inflammatory trigger; must exclude emergently, but doesn't unify the asthma/rhinitis prodrome.
- ABPA: Fits mold exposure and refractory asthma, but rarely causes pleuritic pain or systemic features; check Aspergillus-specific IgE and total IgE.
- Eosinophilic myocarditis/occult cardiomyopathy: Fits exertional pain radiating to back and family history; troponin/BNP/TTE are mandatory.

Key Pivot: The peripheral eosinophil count. Marked eosinophilia (>10% or >1.5 ×10⁹/L) converts this from a PE workup into an eosinophilic systemic disease workup and mandates cardiac involvement screening.

Next Move: Simultaneous, not sequential — CTPA (with HRCT sequences), ECG, hs-troponin, BNP, and urgent CBC with differential. If eosinophilia is confirmed, add TTE and ANCA.

Teaching Pearl: New refractory asthma in an adult is a red flag, not a diagnosis endpoint. In suspected EGPA, chest pain is myocarditis until proven otherwise — always check troponin.

Round 2

User:

Stage 2:
(Timestamp: Admission / Day 1)
Physical Exam: Distressed, febrile 37.2°C, HR 101 bpm (tachycardia), BP 133/68 mmHg, RR 20/min, SpO2 95% on room air. JVP ~7 cm H2O. Lungs clear without wheezing/rales. Heart: Tachycardic, regular, no murmurs/rubs. Chest wall non-tender. Abdomen soft, non-tender, no organomegaly. No rash or pedal edema.
Initial Laboratory & Imaging Workup:
- CBC & Differential: WBC 14,700/µL with 39.6% Eosinophils, yielding an extreme Absolute Eosinophil Count (AEC) of 5,820/µL (normal 0-500/µL)!
- Biomarkers: D-Dimer 632 ng/L, High-Sensitivity Troponin T 606 ng/L (severely elevated!), hs-CRP 12.1 mg/L, ESR 31 mm/hr. COVID-19 PCR & viral panel negative.
- ECG: Sinus tachycardia (101 bpm). Chest X-Ray: Normal.
- CTPA: Excluded PE/dissection, but revealed mediastinal and hilar lymphadenopathy (up to 1.2 cm).

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Extreme absolute hypereosinophilia (AEC 5,820/µL), severe myocardial injury (hs-Troponin T 606 ng/L), and mediastinal/hilar lymphadenopathy, with PE/dissection ruled out on CTPA.

Differential Diagnoses:
1. EGPA with Eosinophilic Myocarditis (65%): Unifies adult-onset asthma, rhinitis, extreme eosinophilia, lymphadenopathy, and acute myocardial injury (the primary cause of EGPA mortality).
2. Idiopathic Hypereosinophilic Syndrome (HES) (20%): Marked AEC >1500/µL with end-organ cardiac toxicity, though pre-existing asthma strongly favors EGPA.
3. ABPA with Secondary Carditis (10%): Mold history and extreme eosinophilia; direct severe cardiac involvement remains rare.
4. Reactive/Parasitic Eosinophilic Myocarditis (5%): Eosinophilic surge with cardiac tropism, less likely given the long asthma prodrome.

Prioritized Next Steps:
1. Transthoracic Echocardiogram / Cardiac MRI: Evaluate LV function, wall motion abnormalities, and myocardial inflammation/thrombus.
2. Immediate High-Dose Corticosteroid Pulse Therapy: Crucial to stop ongoing eosinophilic cardiotoxicity and necrosis.
3. ANCA Panel (MPO/PR3): Subtype EGPA vasculitis status.
4. Total IgE & Aspergillus-specific IgE/IgG: Evaluate for mold-induced disease.
5. FIP1L1-PDGFRA Testing / Bone Marrow Evaluation: Exclude primary clonal hypereosinophilia.

Attending:

Hello Attending Consultant here

Top 3 DDx:
1. EGPA with eosinophilic myocarditis (asthma + AEC 5820 + TnT 606)
2. Idiopathic HES with cardiac involvement
3. Parasitic/reactive eosinophilic myocarditis (less likely)

Critique/Improvements (6 points):
- Pulse steroids indicated urgently for cardiac toxicity, but obtain blood cultures + strongyloides serology/stool first to avoid hyperinfection.
- Prioritize CMR over TTE alone for late gadolinium enhancement/pattern of eosinophilic myocarditis; add strain imaging.
- ANCA + IgE/Aspergillus STAT; FIP1L1-PDGFRA PCR before marrow.
- Add BNP, continuous telemetry, and early cardio consult for possible endomyocardial biopsy if CMR nondiagnostic.
- Lymphadenopathy warrants peripheral smear review for blasts/clonal markers.
- Hold empiric anticoagulation pending thrombus exclusion on imaging.

Expert:

Hello, Expert Clinician here.

Best Unifying Diagnosis: EGPA presenting with acute eosinophilic myocarditis — the single most lethal complication. Asthma prodrome, AEC 5,820/µL, troponin 606 ng/L, and clear lungs form a classic picture. The "asthma" was vasculitis all along; the vaccine was likely a trigger, not the cause.

Top Differentials:
- Idiopathic HES with cardiac involvement: Fits hypereosinophilia and cardiotoxicity; disfavored by prominent asthma/rhinitis. Requires exclusion of clonal (FIP1L1-PDGFRA) and lymphocytic variants.
- ABPA: Explains mold-linked refractory asthma and eosinophilia but essentially never produces this degree of troponin elevation.
- Reactive/parasitic eosinophilia (e.g., Strongyloides): Must exclude before immunosuppression — steroids in undiagnosed Strongyloides are fatal.

Key Pivot: The eosinophil count of Stage 2 confirms Stage 1's red flag. Cardiac involvement (troponin 606) escalates this from diagnostic workup to organ-saving emergency.

Next Move: Immediate pulse corticosteroids after drawing blood cultures and Strongyloides serology. Simultaneous CMR with LGE to characterize myocarditis and exclude apical thrombus; ANCA, FIP1L1-PDGFRA PCR, and telemetry.

Teaching Pearl: In hypereosinophilia, troponin elevation is eosinophilic myocarditis until proven otherwise — treatment (steroids) must not await diagnostic completion, but always exclude Strongyloides first.

Round 3

User:

Stage 3:
(Timestamp: Hospital Days 1-2)
Troponin Kinetics & Cardiac Imaging:
- Troponin Peak: High-sensitivity Troponin T peaked at 780 ng/L (2 hours post-admission) before declining to 664 ng/L at 6 hours.
- Invasive Coronary Angiography: Normal coronary arteries without obstructive CAD or luminal thrombosis (MINOCA phenotype).
- Cardiac MRI (CMR): T2-weighted & Late Gadolinium Enhancement (LGE) showed diffuse enhancement of parietal and visceral pericardium with subendocardial/myocardial edema in basal anteroseptal and anterolateral walls, plus expanded extracellular volume (ECV 38%), pathognomonically establishing Eosinophilic Myopericarditis.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
CMR pathognomonically confirms acute eosinophilic myopericarditis (subendocardial edema, diffuse pericardial LGE, expanded ECV) with normal coronary arteries (MINOCA) in a patient with adult-onset asthma, rhinitis, and extreme hypereosinophilia (AEC 5,820/µL).

Differential Diagnoses:
1. EGPA with Eosinophilic Myopericarditis (80%): Fully unifies the adult-onset asthma prodrome, allergic rhinitis, marked hypereosinophilia, and life-threatening cardiac involvement.
2. Idiopathic Hypereosinophilic Syndrome (HES) (12%): Marked hypereosinophilia with cardiac toxicity, but less favored due to the classic pre-existing asthma/rhinitis prodrome.
3. Hypersensitivity/Reactive Eosinophilic Myocarditis (5%): Vaccine- or drug-induced eosinophilic surge; less likely to account for the preceding chronic asthma.
4. Clonal/Myeloid Neoplasm with Eosinophilia (3%): Primary eosinophilic driver, requiring molecular exclusion.

Prioritized Next Steps:
1. Urgent Immunosuppression: Pulse Methylprednisolone (1g IV daily x 3 days) combined with Rituximab or Cyclophosphamide for severe organ-threatening EGPA.
2. Telemetry / Rhythm Monitoring: High risk for AV blocks and lethal ventricular arrhythmias.
3. Empiric Ivermectin / Strongyloides Testing: Prevent hyperinfection before heavy immunosuppression.
4. ANCA (MPO/PR3) & FIP1L1-PDGFRA Testing: For disease subtyping and targeted therapy.
5. Urinalysis & Urine Protein/Creatinine Ratio: Screen for concurrent necrotizing glomerulonephritis.

Attending:

Hello Attending Consultant here

Top 3 DDx:
1. EGPA with eosinophilic myopericarditis (asthma + AEC 5820 + CMR-proven)
2. Idiopathic HES with cardiac involvement
3. Hypersensitivity eosinophilic myocarditis (vaccine-triggered)

Critique/Improvements (6 points):
- Pulse methylprednisolone first-line and immediate after Strongyloides serology/stool; do not delay for full serologies.
- Prefer RTX over CYC for induction in cardiac EGPA (ANCA-agnostic efficacy, lower toxicity); reserve CYC for refractory/life-threatening cases.
- Add urgent TTE for LVEF, strain, and apical thrombus; anticoagulate only if thrombus confirmed.
- Obtain ANCA, IgE, FIP1L1-PDGFRA, and full EGPA staging (UA, P/Cr, nerve conduction, ENT) concurrently.
- Continuous telemetry + early HF therapy (BB/ACEI) if EF reduced; serial hs-Tn/BNP.
- Defer bone marrow unless FIP1L1+ or blasts on smear; lymphadenopathy is reactive until proven otherwise.

Expert:

Hello, Expert Clinician here.

Best Unifying Diagnosis: EGPA with acute eosinophilic myopericarditis — CMR (subendocardial LGE, ECV 38%, MINOCA) is essentially pathognomonic in the context of adult-onset asthma, allergic rhinitis, and AEC 5,820/µL. This represents ANCA-negative "vasculitic EGPA" driven by tissue eosinophilic toxicity, the phenotype most associated with cardiac death.

Top Differentials:
- Idiopathic HES with myocarditis: Nearly identical cardiac picture, but lacks the asthma/rhinitis prodrome; requires exclusion of FIP1L1-PDGFRA (clonal) and T-cell (lymphocytic) variants.
- Hypersensitivity/vaccine-triggered eosinophilic myocarditis: Fits temporal association and myopericarditis, but does not explain the 1-year steroid-refractory asthma. Likely a trigger, not the root cause.
- Parasitic (Strongyloides) myocarditis: Must actively exclude before immunosuppression; steroids here are lethal if undiagnosed.

Key Pivot: CMR converts "suspected cardiac involvement" into confirmed eosinophilic myopericarditis — an absolute indication for immediate, aggressive immunosuppression independent of ANCA status.

Next Move: Immediate pulse methylprednisolone after Strongyloides serology/stool (empiric ivermectin if delayed), followed by rituximab (cardiac EGPA) and concurrent FIP1L1-PDGFRA testing, telemetry, and TTE to exclude apical thrombus.

Teaching Pearl: In eosinophilic myocarditis, clean coronaries (MINOCA) are expected. Delaying steroids to "complete the workup" is the most common fatal error — treat first, subtype later.

Round 4

User:

Stage 4:
(Timestamp: Hospital Days 3-5)
Autoantibody & Pathologic Confirmation:
- ANCA (MPO & PR3): NEGATIVE (ANCA-negative EGPA phenotype with predominant cardiac involvement!).
- RF, anti-CCP, dsDNA, SSA/SSB negative. ANA positive at 1:320. Aspergillus IgE, Galactomannan, Beta-D-Glucan, QuantiFERON-TB Gold, Hepatitis C, Strongyloides IgG all negative. C3/C4 normal.
- Sinus CT: Bilateral maxillary sinus mucosal disease with air-fluid levels (rhinosinusitis). ENT exam showed no endonasal biopsy sites.
- Endomyocardial Biopsy (EMB): Histopathology demonstrated interstitial and perivascular eosinophilic inflammation with loose eosinophilic granulomas in visceral pericardium/myocardium, pathognomonically confirming Eosinophilic Granulomatosis with Polyangiitis (EGPA).

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Endomyocardial biopsy pathognomonically confirms EGPA (eosinophilic inflammation with loose granulomas). ANCA is negative, confirming the ANCA-negative phenotype characterized by high cardiotoxicity risk. Strongyloides and infectious screens are negative.

Differential Diagnoses:
1. EGPA (ANCA-Negative Phenotype) (95%): Biopsy-proven eosinophilic myopericarditis with granulomas, asthma prodrome, rhinosinusitis, and extreme hypereosinophilia.
2. Idiopathic Hypereosinophilic Syndrome (HES) (4%): Excluded by presence of tissue granulomas, rhinosinusitis, and chronic asthma prodrome.
3. Hypersensitivity/Drug-Induced Myocarditis (1%): Excluded by tissue granulomas and preceding 1-year asthma/rhinitis course.

Prioritized Management Steps:
1. Induction Immunosuppression: Transition from IV pulse steroids to oral prednisone (1 mg/kg/day) plus Rituximab or Cyclophosphamide (Five-Factor Score = 1 due to cardiac involvement).
2. PJP Prophylaxis: Initiate Trimethoprim-Sulfamethoxazole during intense immunosuppression.
3. Cardioprotective Regimen: Start ACE inhibitor and beta-blocker as tolerated; schedule serial echocardiograms to assess recovery and rule out late thrombosis.
4. Thromboprophylaxis: Administer prophylactic anticoagulation until hypereosinophilia fully resolves.
5. Long-Term Plan: Coordinate Rheumatology/Cardiology care and evaluate future anti-IL-5 therapy (e.g., Mepolizumab) for steroid-sparing maintenance.

Attending:

Hello Attending Consultant here

Top 3 DDx:
1. Biopsy-proven ANCA-negative EGPA with eosinophilic myopericarditis
2. Idiopathic HES (granulomas/rhinosinusitis effectively exclude)
3. Hypersensitivity myocarditis (excluded by chronic prodrome + granulomas)

Critique/Improvements (6 points):
- Confirm FFS=1 (cardiac only); start RTX 375 mg/m² weekly ×4 preferentially over CYC (superior cardiac EGPA data, fertility/toxicity profile).
- Continue high-dose steroids (1 mg/kg) with slow taper; add PCP/PJP + GI prophylaxis immediately.
- Serial TTE + CMR at 3 months for LVEF recovery/thrombus; anticoagulate fully only if thrombus or persistent AEC >1500.
- Screen full EGPA extent (UA, EMG/NCS, PFTs) even if asymptomatic.
- Plan early mepolizumab (anti-IL-5) for steroid-sparing maintenance once induction complete.
- Multidisciplinary EGPA clinic follow-up; monitor for late cardiomyopathy/arrhythmia.

Expert:

Hello, Expert Clinician here.

Best Unifying Diagnosis: Biopsy-proven EGPA (ANCA-negative phenotype) presenting as life-threatening eosinophilic myopericarditis. The triad of late-onset asthma, rhinosinusitis, extreme hypereosinophilia, and myocardial granulomas is definitive. ANCA negativity confirms the "tissular" phenotype characterized by eosinophil-mediated organ toxicity rather than classic vasculitis, explaining the dominant cardiac involvement and absent renal/neurologic disease.

Top Differentials:
- Idiopathic HES with cardiac involvement: Nearly identical clinically but excluded by the asthma prodrome, rhinosinusitis, and granulomatous inflammation on biopsy.
- Hypersensitivity/drug or vaccine-induced myocarditis: Excluded by the chronic prodrome and granulomas; likely acted as a trigger, not the etiology.
- ABPA with secondary carditis: Excluded by negative Aspergillus serologies and the presence of vasculitic granulomas.

Key Pivot: The EMB. It converts a highly probable syndrome into a confirmed diagnosis, locks in the ANCA-negative cardiac phenotype, and mandates aggressive, organ-directed immunosuppression rather than symptomatic care.

Next Move: Induction with high-dose corticosteroids plus rituximab (superior in cardiac EGPA), early transition to mepolizumab for steroid-sparing maintenance, and cardiology co-management with serial TTE/CMR.

Teaching Pearl: In EGPA, ANCA negativity does not mean milder disease — it predicts the opposite. ANCA-negative patients carry the highest risk of fatal cardiac involvement.

Round 5

User:

Stage 5:
(Timestamp: Follow-up & Discharge)
Management & Long-Term Outcome:
- Immediate Treatment: High-Dose IV Methylprednisolone pulse therapy, resulting in complete resolution of blood eosinophilia (0/µL), troponin decline, and chest pain resolution.
- Long-Term Course & Maintenance: Initiated IV Cyclophosphamide monthly. Developed recurrent pericardial effusions requiring pericardiocentesis and pericardial window. Managed with slow prednisone taper, Azathioprine, and IL-1 Receptor Antagonist (Anakinra), achieving complete clinical remission and cardiac stability.

Resident:

Hello, Chief Resident here.

Resident:

Updated Key Findings:
Biopsy-proven ANCA-negative EGPA with initial severe eosinophilic myopericarditis now in clinical remission. The patient experienced recurrent pericardial effusions requiring pericardiocentesis and pericardial window, successfully stabilized with pulse methylprednisolone, cyclophosphamide, azathioprine, slow steroid taper, and an IL-1 receptor antagonist (Anakinra).

Final Diagnosis & Subtype:
1. ANCA-Negative Eosinophilic Granulomatosis with Polyangiitis (EGPA) with Cardiac Involvement & Recurrent Pericardial Effusion (100%): Classic presentation of the ANCA-negative phenotype characterized by predominant tissue eosinophil infiltration, severe endomyocardial toxicity, and persistent pericardial inflammation responsive to IL-1 blockade.

Long-Term Management Plan:
1. Maintenance Immunosuppression: Continue Azathioprine and Anakinra for pericardial stability; consider transition to anti-IL-5 therapy (Mepolizumab 300 mg subcutaneous monthly) for chronic EGPA and asthma control.
2. Steroid Taper: Continue slow Prednisone weaning with close monitoring of clinical symptoms, AEC, hs-CRP, and troponin levels.
3. Cardiovascular & Multidisciplinary Surveillance: Schedule serial TTE at 3 and 6 months to evaluate LVEF, wall motion, and pericardial fluid; ongoing co-management by Rheumatology, Cardiology, and Pulmonology.
4. Pneumocystis Jirovecii Prophylaxis: Maintain TMP-SMX until Prednisone dose is reduced to <10 mg/day.

Attending:

Final Diagnosis:
1. Biopsy-confirmed ANCA-negative EGPA with refractory eosinophilic myopericarditis and recurrent pericardial effusion, successfully brought into remission with pulse steroids, CYC, azathioprine, and anakinra (IL-1 blockade).

Critique/Improvements (6 points):
- Anakinra for refractory EGPA-associated pericarditis is a novel, high-yield strategy; highlight its dual benefit for pericardial inflammation + IL-1β pathway in systemic vasculitis.
- Transition from CYC/AZA to mepolizumab (300 mg q4w) as primary steroid-sparing agent for long-term remission and asthma/rhinosinusitis control.
- Continue PJP prophylaxis (TMP-SMX) while on dual immunosuppression/steroids.
- Serial TTE + CMR at 6–12 months to monitor LV ejection fraction, LGE regression, and pericardial thickening/constriction risk.
- Maintain multidisciplinary care (Rheumatology, Cardiology, Allergy/Pulm) with tight target: AEC <150/µL, normal hs-Tn, zero symptoms.
- Ensure bone health (calcium/vitamin D/bisphosphonate) and cardiovascular risk factor optimization given prolonged steroid exposure.

Final Diagnosis: Biopsy-proven ANCA-negative EGPA presenting as severe eosinophilic myopericarditis and steroid/CYC-refractory recurrent pericarditis, successfully controlled with Anakinra-assisted immunosuppression.

Clinical Summary & Unifying Analysis: This case illustrates the classic "tissular" ANCA-negative EGPA phenotype: a 1-year prodrome of late-onset asthma and rhinosinusitis culminating in severe hypereosinophilic cardiotoxicity without vasculitic renal or nerve involvement. ANCA-negative disease carries the highest mortality risk due to eosinophilic myocardial infiltration, necrosis, and fibrosis. The post-induction course was complicated by recurrent pericarditis—a recognized manifestation of persistent visceral pericardial eosinophilic inflammation—which proved refractory to standard disease-modifying agents but responded dramatically to IL-1 receptor antagonism (Anakinra), highlighting the emerging role of anti-IL-1 therapy in post-inflammatory and vasculitic pericardial syndromes.

Key Long-Term Recommendations:
- Biologic Transition: Initiate Mepolizumab 300 mg SC monthly (anti-IL-5) to maintain asthma/EGPA remission and facilitate complete steroid withdrawal.
- Pericardial Surveillance: Monitor for chronic constriction with serial TTE, cardiac MRI, and clinical assessments.
- Infection & Bone Health: Continue PJP prophylaxis and initiate anti-osteoporotic therapy until steroid taper is complete.

Teaching Pearl: In ANCA-negative EGPA with cardiac involvement, clearing peripheral eosinophils is only step one. Local tissue inflammation can persist and trigger recurrent pericardial disease, where IL-1 blockade offer a life-saving adjunct when standard immunosuppression fails.

Attending:

Hello Attending Consultant here

Top 3 DDx:
1. Biopsy-proven ANCA-neg EGPA (myopericarditis + recurrent pericarditis)
2. Idiopathic HES (excluded by granulomas/rhinosinusitis)
3. Isolated eosinophilic pericarditis (excluded by systemic prodrome)

Critique/Improvements (6 points):
- Anakinra is appropriate for refractory pericarditis (IL-1 driven); continue until effusion-free ×3 mo then taper.
- Switch maintenance from AZA to mepolizumab 300 mg q4wk ASAP for superior EGPA/asthma control and steroid-sparing.
- CYC induction complete—limit cumulative dose; no further pulses needed in remission.
- Serial CMR (not just TTE) at 6 mo to quantify LGE regression and exclude constriction.
- Maintain PJP prophylaxis + bone protection (bisphosphonate) through prednisone <5 mg.
- Target AEC <150/µL, hs-Tn/BNP normalization; lifelong cardio-rheum co-management for late arrhythmia/HF risk.

Expert:

Hello, Expert Clinician here.

Best Unifying Diagnosis: ANCA-negative EGPA with eosinophilic myopericarditis complicated by recurrent eosinophilic pericarditis, now in remission. This is the classic "tissular" phenotype — peripheral eosinophils cleared with steroids, yet visceral pericardial inflammation persisted, explaining refractory effusions responsive to IL-1 blockade (anakinra). The 1-year "asthma" was the vasculitic prodrome all along.

Top Differentials (all now excluded):
- Idiopathic HES (excluded by granulomas, rhinosinusitis).
- Hypersensitivity myocarditis (excluded by chronic prodrome).
- ABPA (excluded by serologies and biopsy).

Key Pivot: The EMB (Stage 4) confirmed EGPA, but the clinical pivot was recurrent pericardial effusions despite CYC/AZA — revealing compartmentalized pericardial inflammation unresponsive to conventional agents, and identifying anakinra as disease-saving.

Next Move: Transition to mepolizumab (anti-IL-5) for durable steroid-free EGPA/asthma control, continue anakinra until effusion-free for 3 months, serial CMR to exclude constrictive evolution, and maintain lifelong cardio-rheumatology surveillance for late fibrosis/arrhythmia.

Teaching Pearl: In EGPA, normalizing the eosinophil count does not equal treating the disease. Tissue-resident eosinophilic inflammation — especially pericardial — can persist silently; recurrent effusion after apparent remission should prompt IL-1 blockade, not reflex steroid escalation.

Top 15 Takeaways for Clinicians

  1. Late-Onset Adult Asthma Red Flag: New-onset or rapidly escalating adult asthma accompanied by allergic rhinitis and systemic symptoms is a major clinical red flag for the prodromal phase of Eosinophilic Granulomatosis with Polyangiitis (EGPA).
  2. Severe Absolute Hypereosinophilia: An Absolute Eosinophil Count (AEC) exceeding 1,500/µL (or >10% of total WBC count) in the setting of dyspnea and pleuritic chest pain mandates immediate investigation for multi-organ tissue infiltration.
  3. High Mortality Risk of ANCA-Negative Phenotype: ANCA-negative EGPA represents the "tissular" phenotype, characterized by direct eosinophilic cytotoxicity; it carries a significantly higher risk of life-threatening cardiac involvement than ANCA-positive EGPA.
  4. Mandatory Troponin Screening in EGPA: In any patient with suspected or confirmed EGPA, pleuritic or exertional chest pain must be assumed to be eosinophilic myopericarditis until proven otherwise, requiring immediate high-sensitivity troponin measurement.
  5. MINOCA Presentation in Eosinophilic Myocarditis: Invasive coronary angiography in acute eosinophilic myocarditis typically reveals completely normal coronary arteries without luminal obstruction or thrombosis (MINOCA phenotype).
  6. Pathognomonic Cardiac MRI (CMR) Features: Cardiac MRI demonstrates subendocardial and myocardial late gadolinium enhancement (LGE), myocardial T2 edema, diffuse pericardial enhancement, and expanded extracellular volume (ECV >32%), establishing myopericarditis.
  7. Emergency Pulse Corticosteroids: Severe eosinophilic myocarditis represents an organ-threatening medical emergency; high-dose pulse Methylprednisolone (500–1,000 mg IV daily x 3 days) must be initiated immediately to halt active myocardial necrosis.
  8. Mandatory Pre-Steroid Strongyloides Exclusion: Prior to initiating high-dose systemic immunosuppression in extreme eosinophilia, Strongyloides stercoralis serology and stool PCR must be obtained to prevent fatal hyperinfection syndrome.
  9. Endomyocardial Biopsy (EMB) Diagnostic Gold Standard: EMB confirming perivascular eosinophilic infiltration, myocardial necrosis, and loose eosinophilic granulomas provides definitive histopathologic confirmation of cardiac EGPA.
  10. Induction Therapy for Cardiac EGPA: Remission induction for severe organ-threatening cardiac EGPA involves high-dose IV glucocorticoids combined with monthly IV Cyclophosphamide or Rituximab.
  11. Management of Recurrent Pericardial Effusions: Pericardial involvement in EGPA can manifest as persistent or recurrent pericardial effusions requiring therapeutic pericardiocentesis, pericardial window creation, and targeted anti-inflammatory therapy.
  12. Targeted IL-1 Receptor Antagonism (Anakinra): In refractory post-inflammatory or vasculitic pericarditis complicating EGPA, Anakinra (IL-1 receptor antagonist) offers a highly effective, steroid-sparing targeted therapy to suppress persistent pericardial inflammation.
  13. Mepolizumab (Anti-IL-5) Maintenance Therapy: Mepolizumab (300 mg SC monthly) directly targets interleukin-5 to deplete eosinophils, serving as the FDA-approved primary biologic for long-term EGPA remission maintenance and asthma control.
  14. Persistent Tissue Eosinophilia Risk: Normalization of peripheral blood eosinophil counts under systemic steroid therapy does not guarantee complete resolution of tissue-resident eosinophilic inflammation in the myocardium or pericardium.
  15. Long-Term Cardiovascular & Multidisciplinary Surveillance: Patients recovering from eosinophilic myopericarditis require joint Rheumatology-Cardiology co-management with serial echocardiography and CMR to screen for late myocardial fibrosis, restrictive cardiomyopathy, or constrictive pericarditis.